Sabbah Hani N, Wang Mengjun, Gupta Ramesh C, Rastogi Sharad, Ilsar Itamar, Sabbah Michael S, Kohli Smita, Helgerson Sam, Lee Randall J
JACC Heart Fail. 2013 Jun;1(3):252-8. doi: 10.1016/j.jchf.2013.02.006.
The study tested the hypothesis that augmentation of the left ventricular (LV) wall thickness with direct intramyocardial injections of alginate hydrogel implants (AHI) reduces LV cavity size, restores LV shape, and improves LV function in dogs with heart failure (HF).
Progressive LV dysfunction, enlargement, and chamber sphericity are features of HF associated with increased mortality and morbidity.
Studies were performed in 14 dogs with HF produced by intracoronary microembolizations (LV ejection fraction [EF] <30%). Dogs were randomized to AHI treatment (n = 8) or to sham-operated control (n = 6). During an open-chest procedure, dogs received either intramyocardial injections of 0.25 to 0.35 ml of alginate hydrogel (Algisyl-LVR, LoneStar Heart, Inc., Laguna Hills, California) or saline. Seven injections were made ∼ 1.0 to 1.5 cm apart (total volume 1.8 to 2.1 ml) along the circumference of the LV free wall halfway between the apex and base starting from the anteroseptal groove and ending at the posteroseptal groove. Hemodynamic and ventriculographic measurements were made before treatment (PRE) and repeated post-surgery for up to 17 weeks (POST).
Compared to control, AHI significantly reduced LV end-diastolic and end-systolic volumes and improved LV sphericity. AHI treatment significantly increased EF (26 ± 0.4% at PRE to 31 ± 0.4% at POST; p < 0.05) compared to the decreased EF seen in control dogs (27 ± 0.3% at PRE to 24 ± 1.3% at POST; p < 0.05). AHI treatment was well tolerated and was not associated with increased LV diastolic stiffness.
In HF dogs, circumferential augmentation of LV wall thickness with AHI improves LV structure and function. The results support continued development of AHI for the treatment of patients with advanced HF.
本研究检验了以下假设,即通过心肌内直接注射藻酸盐水凝胶植入物(AHI)增加左心室(LV)壁厚度,可减小左心室腔大小、恢复左心室形状并改善心力衰竭(HF)犬的左心室功能。
进行性左心室功能障碍、扩大和心室球形化是心力衰竭的特征,与死亡率和发病率增加相关。
对14只通过冠状动脉内微栓塞产生心力衰竭的犬进行研究(左心室射血分数[EF]<30%)。犬被随机分为AHI治疗组(n = 8)或假手术对照组(n = 6)。在开胸手术过程中,犬接受心肌内注射0.25至0.35 ml藻酸盐水凝胶(Algisyl-LVR,LoneStar Heart公司,加利福尼亚州拉古纳希尔斯)或生理盐水。从室间隔前沟开始,到室间隔后沟结束,沿着左心室游离壁在顶点和基部之间中点的圆周,相隔约1.0至1.5 cm进行七次注射(总体积1.8至2.1 ml)。在治疗前(PRE)进行血流动力学和心室造影测量,并在术后重复进行长达17周(POST)。
与对照组相比,AHI显著降低了左心室舒张末期和收缩末期容积,并改善了左心室球形化。与对照组犬EF降低(PRE时27±0.3%至POST时24±1.3%;p<0.05)相比,AHI治疗显著增加了EF(PRE时26±0.4%至POST时31±0.4%;p<0.05)。AHI治疗耐受性良好,且与左心室舒张硬度增加无关。
在心力衰竭犬中,用AHI圆周增加左心室壁厚度可改善左心室结构和功能。结果支持继续研发AHI用于治疗晚期心力衰竭患者。